“Our study…demonstrate[s] an increased risk of HF in MASLD patients and suggests individuals with MASLD and a high metabolic burden should be vigilant about the potential development of HF.”
Conclusion from the 08 January 2025 study published in The European Journal of Heart Failure: “In patients with SLD, those with MASLD show a higher risk of HF, specifically HFpEF. Future studies are warranted to validate the association between HF and MASLD.”
Among patients with steatotic liver disease (SLD), those patients who also have metabolic dysfunction-associated SLD (MASLD) have a significant risk for heart failure (HF), especially HF with preserved ejection fraction (HFpEF), as compared with those without MASLD, investigators from a Taiwan Medical Center reported in the European Journal of Heart Failure.
The cohort included patients aged 20 years and older with chronic liver disease, who were screened from January 2006 to February 2021.
The eligible participants had persistent SLD documented from serial abdominal ultrasound examinations and were categorized into the MASLD group or the non-MASLD group. The primary outcome was new-onset HF.
The cohort included 26,676 patients (median age, 51 years) and 57% were men. The MASLD group had 18,977 patients (71%) and the non-MASLD group had 7,699 patients (29%).”